Hunter Associates Investment Management LLC reduced its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 23.6% in the fourth quarter, according to the company in its most recent filing with the ...
Biogen Inc. closed 41.60% below its 52-week high of $246.44, which the company achieved on February 7th.
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the region's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback